Artelo Biosciences, Inc. - ARTL STOCK NEWS

Artelo Biosciences (Nasdaq: ARTL) presented preclinical data on ART26.12, a fatty acid-binding protein 5 (FABP5) inhibitor, at the 34th Annual International Cannabinoid Research Society Symposium. The data demonstrated ART26.12's effectiveness in reducing pain behaviors caused by breast cancer in preclinical studies. This study is the fourth in a series showing consistent efficacy in various pain models, including oxaliplatin-induced peripheral neuropathy. Artelo aims to initiate human trials following FDA approval of their Investigational New Drug application. Breast cancer often leads to bone metastasis, causing severe pain. ART26.12 offers a novel, non-opioid, non-steroidal treatment option for such pain.

Artelo Biosciences (Nasdaq: ARTL), a clinical-stage pharmaceutical company, presented new preclinical data on ART26.12 at the 57th Annual Scientific Meeting of the British Pain Society. The conference took place from June 4-6, 2024, in Nottingham, UK. ART26.12, a Fatty Acid Binding Protein 5 (FABP5) inhibitor, showed efficacy in reducing breast cancer-induced bone pain and diabetic neuropathy in preclinical models. Effective doses and plasma exposures were consistent with previous data. Artelo plans to submit an Investigational New Drug application to the U.S. FDA this month. This non-opioid, non-steroidal treatment is seen as a promising alternative for pain management.

Artelo Biosciences (Nasdaq: ARTL) presented new pre-clinical data on ART12.11 at the CT-CANN24 conference, demonstrating that ART12.11, a patented cocrystal of CBD and TMP, has comparable pharmacokinetics to Epidiolex in rats. Epidiolex, an FDA-approved oral CBD solution, saw over $845 million in net sales in 2023. ART12.11, in an unoptimized formulation, showed similar CBD levels in plasma to Epidiolex, suggesting potential for a solid dosage form that is preferred for adolescents and adults due to better dosing precision, storage, and transport. Previous animal studies indicated ART12.11 outperformed CBD in stress-induced anxiety and depression with a lower CBD amount. Artelo is developing an optimized tablet form of ART12.11 for clinical studies, aiming to broaden CBD research in larger populations.

Artelo Biosciences, Inc. (Nasdaq: ARTL) reported financial results for Q1 2024, highlighting progress in developing treatments for cancer, pain, dermatologic, and neurological conditions. The company's lead inhibitor, ART26.12, shows promise in treating neuropathic pain. Artelo's cash and investments stood at $7.6 million, with R&D expenses at $1.5 million and a net loss of $2.5 million.

Artelo Biosciences, Inc. (Nasdaq: ARTL) will be presenting at the 2024 Pharma Partnering Summit on May 14th, with CEO Gregory D. Gorgas discussing the company's focus on developing treatments for cancer, pain, dermatologic, and neurological conditions. The summit provides networking and partnership opportunities in the life sciences sector.

Artelo Biosciences announces the publication of a peer-reviewed article highlighting FABP7 as a promising novel target in cancer therapy. The article discusses the role of FABP7 in various cancers, its potential as a validated target in cancer treatment, and the impact of FABP7 inhibition on tumor growth and patient prognosis. Artelo is focused on developing FABP inhibitors for cancer and other serious conditions, with the lead compound ART26.12 showing promising results in preclinical studies for conditions like cancer bone pain and chemotherapy-induced peripheral neuropathy.

Artelo Biosciences CEO, Gregory D. Gorgas, will be a guest on Benzinga All Access on April 23rd at 10:50 AM Eastern Time. Artelo focuses on developing treatments for cancer, pain, dermatologic, and neurological conditions.

Artelo Biosciences, Inc. reports significant achievements in 2023, focusing on key milestones in cancer treatment development. The company completed phase 1b and initiated phase 2a of the Cancer Appetite Recovery Study (CAReS) with ART27.13, advanced ART 26.12 toward IND submission for neuropathic pain treatment, and presented data on the efficacy of ART12.11 in anxiety and depression models. The company also highlighted safety results for ART27.13, published research on its protective properties, and announced positive effects of ART26.12 in neuropathic pain models. Financially, Artelo Biosciences ended 2023 with $10.4 million in cash and investments, with R&D expenses at $5.7 million and a net loss of $9.3 million.

Artelo Biosciences, Inc. (ARTL) presents preclinical dermatology research on ART26.12 to Johnson & Johnson's Innovation Challenge, showcasing potential in treating dermatological conditions beyond cancer and pain. The FABP5 inhibitor, ART26.12, demonstrates positive effects in preclinical psoriasis models, offering promise for future clinical development.